Abstract:Objective:To investigate the role and mechanism of nicotinamide riboside in obesity-related lipotoxic cardiomyopathy.Methods:Male C57BL/6N mice at 8 weeks of age were randomly divided into the normal diet group (control group), high-fat diet group, and high-fat diet with nicotinamide ribose group ( n=10 each). The mice on high-fat diet were modeled for obese mice lipotoxic cardiomyopathy over a24-week feeding. The mice in the high-fat diet with nicotinamide ribose group were administered with 40 mmol/L nicotinamide ribose in drinking water for 12 weeks on top of the high-fat diet. After modeling, all mice were measured for blood pressure of the caudal artery, collected of peripheral blood samples for testing of blood sugar, and lipids, and evaluated for heart function by echocardiography. Then the mice hearts were harvested and subjected to pathological and molecular biological studies. The heart weight and tibia length of the mice were measured by gross photography. The area of mice cardiomyocytes was quantified by staining with wheat germ agglutinin (WGA). Picrosirius red (PSR) staining was used to show the myocardial fibrosis in mice such that the effect of nicotinamide riboside on mice myocardial remodeling was evaluated. The lipid droplets infiltration in mice cardiomyocytes was examined by transmission electron microscopy. The protein expression levels of Sirt1 and Serca2a in mice cardiomyocytes were detected by Western blotting. Results:Compared with the control group, the mice on high-fat diet presented significant increases in body weight, systolic blood pressure, diastolic blood pressure, total cholesterol, triglyceride and LDL-c levels (all P<0.05), and the elevation in these indicators indiced by high fat diet was alleviated by the addition of nicotinamide riboside (all P<0.05). The heart rate and blood sugar level in mice were not affected by high-fat diet with or without nicotinamide riboside. Compared with the control group, the mice on high-fat diet had higher or greater left ventricular ejection fraction and lower ratio of E to A peaks (E/A) on echocardiograpy (both P<0.05), and addition of nicotinamide riboside increased the left ventricular ejection fraction and E/A ratio (both P<0.05). Compared with the control group, the mice on high-fat diet had higher or greater ratio of heart weight to tibia length, cross-sectional area and collagen contents in cardiomyocytes of the left ventricle (all P<0.05), whereas addition of nicotinamide riboside was found to inhibit the myocardial hypertrophy and fibrosis as described above (all P<0.05). Compared with the control group, high-fat diet led to a significant increase in deposition of lipid droplets in the left ventricular myocardium[ (13.8±0.86) /100 μm 2 vs (4.7±0.51) /100 μm 2, P<0.05], while nicotinamide ribose could alleviate such lipid-induced myocardial fibrosis[ (6.2±0.77) /100 μm 2 vs (13.8±0.86) /100 μm 2, P=0.021]. Western blotting showed lower protein expression levels of Sirt1 in the lipotoxic myocardial tissues and sarco (endo) plasmic reticulum Ca 2+-ATPase (Serca2a), along with increased acetylation of Serca2a in mice on high-fat diet compared with the control group (all P<0.05), while nicotinamide riboside was shown to increase Sirt1 and Serca2a expression and promote Serca2a deacetylation (all P<0.05) . Conclusion:Nicotinamide riboside may alleviate high fat-induced lipotoxic cardiomyopathy by promoting Sirt1-mediated deacetylation of Serca2a.

Nicotinamide mononucleotide attenuates HIF-1α activation and fibrosis in hypoxic adipose tissue via NAD+/SIRT1 axis

Nicotinamide mononucleotide attenuates HIF-1a activation and fibrosis in hypoxic adipose tissue <i>via</i> NAD<SUP>+</SUP>/SIRT1 axis

Nicotinamide Mononucleotide Attenuates Isoproterenol-Induced Cardiac Fibrosis by Regulating Oxidative Stress and Smad3 Acetylation.

Nicotinamide Mononucleotide Protects Against High-Fat-diet-induced Atherosclerosis in Mice and Dampens Aortic Inflammation and Oxidative Stress

Nicotinamide mononucleotide alters body composition and ameliorates metabolic disorders induced by a high-fat diet

Nicotinamide Mononucleotide Inhibits Hepatic Stellate Cell Activation to Prevent Liver Fibrosis Via Promoting PGE2 Degradation

Nicotinamide Mononucleotide Prevents Free Fatty Acid-Induced Reduction in Glucose Tolerance by Decreasing Insulin Clearance

Nicotinamide Mononucleotide (NMN) Ameliorates Free Fatty Acid-Induced Pancreatic β-Cell Dysfunction via the NAD+/AMPK/SIRT1/HIF-1α Pathway

Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy

Short-term Administration of Nicotinamide Mononucleotide Preserves Cardiac Mitochondrial Homeostasis and Prevents Heart Failure.

Nicotinamide Mononucleotide Supplementation Alleviates Doxorubicin-Induced Multi-Organ Fibrosis

Alleviation of hepatic insulin resistance and steatosis with NMN via improving endoplasmic reticulum–Mitochondria miscommunication in the liver of HFD mice

Nicotinamide Riboside Protects Against Liver Fibrosis Induced by CCl4 Via Regulating the Acetylation of Smads Signaling Pathway.

Nicotinamide mononucleotide attenuates airway epithelial barrier dysfunction via inhibiting SIRT3 SUMOylation in asthma

NAMPT-mediated NAD+ biosynthesis suppresses activation of hepatic stellate cells and protects against CCl4-induced liver fibrosis in mice

Role of nicotinamide riboside in lipotoxic cardiomyopathy: a mechanistic study

Nicotinamide riboside supplementation exerts an anti-obesity effect and prevents inflammation and fibrosis in white adipose tissue of female diet-induced obesity mice

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

The Role of Metformin and Resveratrol in the Prevention of Hypoxia‐inducible Factor 1α Accumulation and Fibrosis in Hypoxic Adipose Tissue

Nicotinamide Mononucleotide Promotes Osteogenesis and Reduces Adipogenesis by Regulating Mesenchymal Stromal Cells Via the SIRT1 Pathway in Aged Bone Marrow

Nicotinamide Riboside-Driven Modulation of SIRT3/mtROS/JNK Signaling Pathways Alleviates Myocardial Ischemia-Reperfusion Injury